Pediatric Vaccines

New research shows stalled childhood vaccine progress, elevated heart risks linked to COVID-19 vaccines in young men, and rising gastrointestinal disorders during the pandemic.

A national analysis of county-level measles-mumps-rubella vaccination rates from 2017 to 2024 shows a significant decline following the COVID-19 pandemic, with geographic variation and implications for...

New research explores long COVID risks in children, ACIP's expanded RSV vaccine use, U.S. disease resurgence under falling immunization, and long COVID’s burden on health care workers.

A phase 3 study found that the 20-valent pneumococcal conjugate vaccine (PCV20) elicited strong immune responses across all 20 serotypes and had a safety profile comparable with PCV13.

Researchers aimed to describe the most common symptoms of long COVID and the progression of symptoms over time. They presented their findings at IDWeek 2023 in Boston, Massachusetts.

This COVID-19 roundup includes coverage of the FDA’s guidance for the correct Moderna vaccine dosage for pediatric patients, COVID-19 outcomes for patients with hypertension and diabetes, and the risk of...

Researchers aimed to quantify the amount of protection maternal COVID-19 boosters provide during the first 6 months of an infant’s life.

Findings show that children in early childhood are not completing their multidose vaccine series due to some structural barriers.

The FDA approved the new round of vaccines for those 12 years and older and authorized emergency use for children 6 months to 11 years of age.

Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.